“And on a long-term basis, of course, low single digits, consistent with what we've said. But this year had some anomalies. And so neutral for this year. You will see some negative price in the back half of the year.”

In context

“y on the volume side, when you look at that IQVIA data as we've spoken about in the past, there is a disconnect from the induction. And that really, I would call that about a 10-point differential that you need to add to what you're seeing in the data to get to the volume trend. But we still do have favorable price in the quarter and also the first half. And there's really a couple of things going on there. It's really some price gating items that were unique. We also are seeing from some of the information that we've received, the Part D redesign impact will be a little bit more heavily weighted towards the back half of the year. So that was less of a headwind in the first year, but really some pricing gating items. We do expect on an overall basis that pricing to be neutral for Skyrizi. And on a long-term basis, of course, low single digits, consistent with what we've said. But this year had some anomalies. And so neutral for this year. You will see some negative price in the back half of the year. Operator: The next question comes from Gary Nachman with Raymond James. Gary Jay Nachman: Nice quarter. So first, also on Skyrizi. What are you seeing regarding the competitive dynamics in the IL-23 class, especially with J&J's TREMFYA with their new IBD approvals, if that's impacting at all? Or is there just a ton of headroom in the IBD market to absorb that? And then on neuro, it was very strong in 2Q. Is that mainly volume demand driven across the various products? Any changes with gross to nets that are worth noting? And how much more have you been investing behind the neuro franchise overall given such strong growth that you've been seeing there? Jeffrey Ryan Stewart: Yes. So thanks for your question on Skyrizi and the competition. We're quite pleased again with the overall performan”